Mechanisms of resistance to antifungal agents

Manual of Clinical Microbiology: Tenth Edition

Volumn 2-2, Issue , 2022, Pages 2008-2019

  White, Theodore C ^a   Hoot, Samantha J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antifungal agents; C. albicans; Drug resistance; ERG11 gene; Susceptibility testing

Indexed keywords

EID: 84861131437     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1128/9781555816728.ch127     Document Type: Chapter

References (44)

1. Arendrup, M. C., G. Garcia-Effron, C. Lass-Flörl, A. G. Lopez, J.-L. Rodriguez-Tudela, M. Cuenca-Estrella, and D. S. Perlin. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob. Agents Chemother. 54:426-439.
2. Bruno, V. M., and A. P. Mitchell. 2005. Regulation of azole drug susceptibility by Candida albicans protein kinase CK2. Mol. Microbiol. 56:559-573.
3. Coste, A., A. Selmecki, A. Forche, D. Diogo, M.-E. Bougnoux, C. d'Enfert, J. Berman, and D. Sanglard. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6:1889-1904.
4. Coste, A., V. Turner, F. Ischer, J. Morschhauser, A. Forche, A. Selmecki, J. Berman, J. Bille, and D. Sanglard. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139-2156.
5. Coste, A. T., M. Karababa, F. Ischer, J. Bille, and D. Sanglard. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652.
6. Cowen, L. E. 2008. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6:187-198.
7. Cowen, L. E., and W. J. Steinbach. 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7:747-764.
8. Dunkel, N., J. Blass, P. D. Rogers, and J. Morschhauser. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840.
9. Dunkel, N., T. T. Liu, K. S. Barker, R. Homayouni, J. Morschhäuser, and P. D. Rogers. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell 7:1180-1190.
10. Ferreira, M. E., A. L. Colombo, I. Paulsen, Q. Ren, J. Wortman, J. Huang, M. H. Goldman, and G. H. Goldman. 2005. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med. Mycol. 43(Suppl 1):S313-S319.
11. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
12. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-b- d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
13. Harry, J. B., B. G. Oliver, J. L. Song, P. M. Silver, J. T. Little, J. Choiniere, and T. C. White. 2005. Drug- induced regulation of the MDR1 promoter in Candida albicans. Antimicrob. Agents Chemother. 49:2785-2792.
14. Hiller, D., D. Sanglard, and J. Morschhäuser. 2006. Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans. Antimicrob. Agents Chemother. 50:1365-1371.
15. Hoot, S. J., B. G. Oliver, and T. C. White. 2008. Candida albicans UPC2 is transcriptionally induced in response to antifungal drugs and anaerobicity through Upc2p-dependent and -independent mechanisms. Microbiology 154:2748-2756.
16. Howard, S. J., I. Webster, C. B. Moore, R. E. Gardiner, S. Park, D. S. Perlin, and D. W. Denning. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453.
17. Kaur, R., I. Castano, and B. P. Cormack. 2004. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob. Agents Chemother. 48:1600-1613.
18. Manoharlal, R., N. A. Gaur, S. L. Panwar, J. Morschhäuser, and R. Prasad. 2008. Transcriptional activation and increased mRNA stability contribute to overexpression of CDR1 in azole-resistant Candida albicans. Antimicrob. Agents Chemother. 52:1481-1492.
19. Mansfield, B. E., H. N. Oltean, B. G. Oliver, S. E. Leyde, L. Hedstrom, and T. C. White. 2010. Azole drug import requires a transporter in Candida albicans and other pathogenic fungi. Presented at the 10th ASM Conference on Candida and Candidiasis, Miami, Florida, March 23-26, 2010.
20. Marie, C., S. Leyde, and T. C. White. 2008. Cytoplasmic localization of sterol transcription factors Upc2p and Ecm22p in S. cerevisiae. Fungal Genet. Biol. 45:1430-1438.
21. Marie, C., and T. C. White. 2009. Genetic basis of antifungal drug resistance. Curr. Fungal Infect. Rep. 3:163-169.
22. Morschhauser, J., K. S. Barker, T. T. Liu, B. W. J. Bla, R. Homayouni, and P. D. Rogers. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164.
23. Nett, J., L. Lincoln, K. Marchillo, R. Massey, K. Holoyda, B. Hoff, M. VanHandel, and D. Andes. 2007. Putative role of b-1,3 glucans in Candida albicans biofilm resistance. Anti- microb. Agents Chemother. 51:510-520.
24. Odds, F. C., M. E. Bougnoux, D. J. Shaw, J. M. Bain, A. D. Davidson, D. Diogo, M. D. Jacobsen, M. Lecomte, S. Y. Li, A. Tavanti, M. C. Maiden, N. A. Gow, and C. d'Enfert. 2007. Molecular phylogenetics of Candida albicans. Eukaryot. Cell 6:1041-1052.
25. Oliver, B. G., P. M. Silver, C. Marie, S. J. Hoot, S. E. Leyde, and T. C. White. 2008. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology 154:960-970.
26. Oliver, B. G., J. L. Song, J. H. Choiniere, and T. C. White. 2007. cis-acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p. Eukaryot. Cell 6:2231-2239.
27. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
28. Pfaller, M. A., D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, A. Espinel-Ingroff, C. L. Fowler, E. M. Johnson, C. C. Knapp, M. R. Motyl, L. Ostrosky-Zeichner, D. J. Sheehan, and T. J. Walsh. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
29. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
30. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
31. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
32. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
33. Sanglard, D., and J. Bille. 2002. Current understanding of the mode of action and of resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections, p. 349-383. In R. Calderone (ed.), Candida and Candidiasis. ASM Press, Washington, DC.
34. Schubert, S., P. D. Rogers, and J. Morschhäuser. 2008. Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimi- crob. Agents Chemother. 52:4274-4280.
35. Selmecki, A., A. Forche, and J. Berman. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367-370.
36. Selmecki, A., M. Gerami-Nejad, C. Paulson, A. Forche, and J. Berman. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 68:624-641.
37. Verweij, P. E., S. J. Howard, W. J. Melchers, and D. W. Denning. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updates 12:141-147.
38. Verweij, P. E., E. Snelders, G. H. Kema, E. Mellado, and W. J. Melchers. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
39. Walker, L. A., C. A. Munro, I. de Bruijn, M. D. Lenardon, A. McKinnon, and N. A. Gow. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4:e1000040.
40. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistance 14a demethylase in Candida albicans. Antimi- crob. Agents Chemother. 41:1488-1494.
41. White, T. C. 2007. Mechanisms of resistance to antifungal agents, p. 1961-1971. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of Clinical Microbiology, 9th ed., vol. 2. ASM Press, Washington, DC.
42. White, T. C., J. B. Harry, and B. G. Oliver. 2004. Antifungal drug resistance: pumps and permutations, p. 319-338. In J. W. Domer and G. S. Koybayashi (ed.), Human Fungal Pathogens, vol. XII. Springer, Berlin.
43. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
44. Znaidi, S., S. Weber, O. Z. Al-Abdin, P. Bomme, S. Saidane, S. Drouin, S. Lemieux, X. De Deken, F. Robert, and M. Raymond. 2008. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot. Cell 7:836-847.